<?xml version='1.0' encoding='utf-8'?>
<document id="23569370"><sentence text="Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study."><entity charOffset="10-19" id="DDI-PubMed.23569370.s1.e0" text="verapamil" /><entity charOffset="55-67" id="DDI-PubMed.23569370.s1.e1" text="umeclidinium" /><entity charOffset="72-82" id="DDI-PubMed.23569370.s1.e2" text="vilanterol" /><pair ddi="false" e1="DDI-PubMed.23569370.s1.e0" e2="DDI-PubMed.23569370.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s1.e0" e2="DDI-PubMed.23569370.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s1.e0" e2="DDI-PubMed.23569370.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s1.e1" e2="DDI-PubMed.23569370.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s1.e1" e2="DDI-PubMed.23569370.s1.e2" /></sentence><sentence text="The combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist, and vilanterol (VI), a selective long-acting β₂ agonist, is in development for the treatment of chronic obstructive pulmonary disease (COPD)"><entity charOffset="19-31" id="DDI-PubMed.23569370.s2.e0" text="umeclidinium" /><entity charOffset="33-37" id="DDI-PubMed.23569370.s2.e1" text="UMEC" /><entity charOffset="90-100" id="DDI-PubMed.23569370.s2.e2" text="vilanterol" /><pair ddi="false" e1="DDI-PubMed.23569370.s2.e0" e2="DDI-PubMed.23569370.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s2.e0" e2="DDI-PubMed.23569370.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s2.e0" e2="DDI-PubMed.23569370.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s2.e1" e2="DDI-PubMed.23569370.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s2.e1" e2="DDI-PubMed.23569370.s2.e2" /></sentence><sentence text=" This study evaluated the pharmacokinetics, safety and tolerability, and pharmacodynamics of once-daily, inhaled UMEC and UMEC/VI when co-administered with oral verapamil, a moderate P-glycoprotein transporter and moderate cytochrome P450 3A4 (CYP3A4) inhibitor frequently used by patients with COPD and cardiovascular comorbidities"><entity charOffset="161-170" id="DDI-PubMed.23569370.s3.e0" text="verapamil" /><entity charOffset="113-121" id="DDI-PubMed.23569370.s3.e1" text="UMEC" /><entity charOffset="122-130" id="DDI-PubMed.23569370.s3.e2" text="UMEC" /><pair ddi="false" e1="DDI-PubMed.23569370.s3.e1" e2="DDI-PubMed.23569370.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s3.e1" e2="DDI-PubMed.23569370.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s3.e1" e2="DDI-PubMed.23569370.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s3.e2" e2="DDI-PubMed.23569370.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s3.e2" e2="DDI-PubMed.23569370.s3.e0" /></sentence><sentence text="" /><sentence text="Subjects were randomized to one of two 13-day treatment regimens: UMEC 500 μg or UMEC 500 μg/VI 25 μg"><entity charOffset="66-69" id="DDI-PubMed.23569370.s5.e0" text="UMEC" /><entity charOffset="81-84" id="DDI-PubMed.23569370.s5.e1" text="UMEC" /><pair ddi="false" e1="DDI-PubMed.23569370.s5.e0" e2="DDI-PubMed.23569370.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s5.e0" e2="DDI-PubMed.23569370.s5.e1" /></sentence><sentence text=" All subjects received a single tablet containing 240 mg verapamil on each of days 9-13"><entity charOffset="57-66" id="DDI-PubMed.23569370.s6.e0" text="verapamil" /></sentence><sentence text="" /><sentence text="Repeat doses of UMEC and UMEC/VI in combination with and without verapamil were safe and well tolerated"><entity charOffset="65-74" id="DDI-PubMed.23569370.s8.e0" text="verapamil" /><entity charOffset="16-24" id="DDI-PubMed.23569370.s8.e1" text="UMEC" /><entity charOffset="25-33" id="DDI-PubMed.23569370.s8.e2" text="UMEC" /><pair ddi="false" e1="DDI-PubMed.23569370.s8.e1" e2="DDI-PubMed.23569370.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s8.e1" e2="DDI-PubMed.23569370.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s8.e1" e2="DDI-PubMed.23569370.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s8.e2" e2="DDI-PubMed.23569370.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s8.e2" e2="DDI-PubMed.23569370.s8.e0" /></sentence><sentence text=" There was no increase in systemic exposure of UMEC when administered in combination with VI compared to UMEC alone"><entity charOffset="47-50" id="DDI-PubMed.23569370.s9.e0" text="UMEC" /><entity charOffset="105-108" id="DDI-PubMed.23569370.s9.e1" text="UMEC" /><pair ddi="false" e1="DDI-PubMed.23569370.s9.e0" e2="DDI-PubMed.23569370.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s9.e0" e2="DDI-PubMed.23569370.s9.e1" /></sentence><sentence text=" UMEC maximum concentration was similar with or without verapamil; a moderate increase in UMEC area under the curve (approximately 1"><entity charOffset="56-65" id="DDI-PubMed.23569370.s10.e0" text="verapamil" /><entity charOffset="1-9" id="DDI-PubMed.23569370.s10.e1" text="UMEC" /><entity charOffset="90-98" id="DDI-PubMed.23569370.s10.e2" text="UMEC" /><pair ddi="false" e1="DDI-PubMed.23569370.s10.e1" e2="DDI-PubMed.23569370.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23569370.s10.e1" e2="DDI-PubMed.23569370.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s10.e1" e2="DDI-PubMed.23569370.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23569370.s10.e0" e2="DDI-PubMed.23569370.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s10.e0" e2="DDI-PubMed.23569370.s10.e2" /></sentence><sentence text="4-fold) was observed with verapamil"><entity charOffset="26-35" id="DDI-PubMed.23569370.s11.e0" text="verapamil" /></sentence><sentence text=" Verapamil did not increase systemic exposure to VI following administration of the UMEC/VI combination"><entity charOffset="84-92" id="DDI-PubMed.23569370.s12.e0" text="UMEC" /></sentence><sentence text="" /><sentence text="Administration of UMEC and UMEC/VI combination was well tolerated and did not show clinically relevant increases in systemic exposure for either drug"><entity charOffset="18-22" id="DDI-PubMed.23569370.s14.e0" text="UMEC" /><entity charOffset="27-30" id="DDI-PubMed.23569370.s14.e1" text="UMEC" /><pair ddi="false" e1="DDI-PubMed.23569370.s14.e0" e2="DDI-PubMed.23569370.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23569370.s14.e0" e2="DDI-PubMed.23569370.s14.e1" /></sentence><sentence text=" The UMEC/VI combination is unlikely to have a clinically meaningful drug-drug interaction with moderate P-glycoprotein transporter and CYP3A4 inhibitor drugs"><entity charOffset="5-8" id="DDI-PubMed.23569370.s15.e0" text="UMEC" /></sentence><sentence text="" /></document>